Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Head and Neck Neoplasms 12Squamous Cell Carcinoma of Head and Neck 9Stomach Neoplasms 4Salivary Gland Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Leukemia, Myeloid, Acute 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Tobacco Use Disorder 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma, Ovarian 1Teratoma 1Sezary Syndrome 1

Interventions

trametinib 1dabrafenib 1Valganciclovir 1Polymerase Chain Reaction 1Biopsy 14-phenylbutyric acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Polymerase Chain Reaction × Head & Neck × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡